How p53 helps protect against cancer by controlling genetic elements in fruit flies
Official title: Functional activation of p53 by reverse transcriptase processes
Funded at Southern Methodist University · NIH-11430869 · Data updated 2026-11-12
This grant explores how the tumor-suppressor protein p53 works to keep cells from turning cancerous, using fruit flies and other models to learn how p53 controls mobile genetic elements called retrotransposons and how this might relate to human cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Southern Methodist University NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project start | August 1, 2026 |
| Project end | March 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $390,228 |
| NIH project number | 1R35GM166193-01 |
| Project ID | NIH-11430869 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with cancers involving p53 mutations or dysregulated transposons could benefit from insights drawn from this research.
✕Less likely to help
Individuals without cancer or without p53-related issues may not directly benefit from this basic science study.
What this research studies
Researchers will use the fruit-fly model to study how p53 helps restrain retrotransposons, aiming to uncover ancient, conserved functions of p53 that may influence human cancer. They will compare human and animal p53 genes in how they react when transposons are active, and examine how p53-related mechanisms operate in germline cells of flies and fish. The project builds on findings that p53 can suppress transposons and that cancer-associated p53 mutations fail to do so, providing insight into cancer prevention strategies. By linking p53 activity to transposon control, the work seeks to illuminate new angles for preventing or mitigating oncogenic processes in humans.
Why it matters
Potential benefit: If successful, this work could reveal new ways that p53 helps prevent cancer by keeping genetic elements in check, potentially guiding novel prevention or treatment strategies.
How similar studies have gone: Previous studies showed p53 can suppress transposons and that mutant p53 genes from cancer patients fail to do so, supporting a translational relevance for humans.
Where this research is happening
-
Southern Methodist University
Dallas, United States Active
Researchers
- Principal investigator: Wylie, Annika Dawn — Southern Methodist University
- Study coordinator: Wylie, Annika Dawn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.